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| INTRODUCTION
Type 1 diabetes (T1D) requires life-long insulin replacement therapy with continuous health care support to achieve optimal blood glucose (BG) control, defined as glycated hemoglobin (HbA1c) <7%, and reduce the risk of long-term diabetes-related complications.
1,2 Despite remarkable advances in diabetes treatment, patients continue to struggle in achieving glycaemic targets, with an average HbA1c remaining >8.0%
and a high frequency of severe and non-severe hypoglycaemia events. 3, 4 Self-management in T1D involves multiple day-to-day tasks including, but not limited to, insulin dose adjustments, self-monitoring of BG, hypoglycaemia management and carbohydrate (CHO) counting.
These tasks can be challenging 5, 6 and compliance is often limited. 7, 8 Closed-loop automated insulin delivery systems (CLS), also called the "artificial pancreas," are one of the most promising therapies for T1D, with the first system recently approved by the Food and Drug Association (FDA) in the US. 9 CLS could help reduce the burden associated with day-to-day self-management while improving glucose control by reducing both hypoglycaemia and hyperglycaemia. 10 In this system, insulin-only (single-hormone CLS) or insulin and a second drug, typically glucagon (dual-hormone CLS) infusion rates are regulated based on algorithm-generated recommendations relying on con- , and reducing the time in hyperglycaemia in most studies. [11] [12] [13] [14] [15] [16] [17] However, one of the main challenges that remains with CLS is postprandial glucose control.
With CLS, several strategies have been proposed to control postmeal glucose excursions: (1) CLS with a classical CHO content matched meal bolus announcement implemented by the patient, also called hybrid CLS; (2) CLS with a meal announcement strategy that is completely or partially independent of the CHO meal content (simplified meal bolus); (3) a fully automated CLS with no meal announcement. Although a fully automated CLS approach would be optimal to alleviate the burden associated with meal glucose control, it should be achieved without compromising glucose control. In the meantime, several simplified strategies are currently being developed and tested.
The objective of this literature review is to examine current strategies for simplification of meal glucose control in the context of closed-loop insulin delivery with or without adjunct therapy in adults and children with T1D. Effective post-meal glucose control and current challenges will also be discussed.
| POSTPRANDIAL GLUCOSE CONTROL
Controlling postprandial glucose excursions is identified as a key component of achieving a recommended HbA1c. 2, 18 The 2-hours post-meal glucose target in individuals with T1D is between 5 and 10 mmol/L in most patients. 2, 19 CHO content of meals is the main determinant of postprandial glucose excursion. 20, 21 Consequently, in conventional T1D therapy, prandial insulin doses depend on the CHO content of each ingested meal: before each food intake, patients need to estimate the CHO content of their food (CHO counting) and to deliver insulin boluses proportional to the CHO content, based on their individualized insulin-to-CHO ratios. 2 Precision of CHO counting is associated with better glycaemic control. 22 However, it is also a challenging task for patients. 6 The average error in CHO counting is approximately 20%, with most patients underestimating their meal content, while poor CHO counting precision has been shown to be associated with increased glycaemic variability and time in hyperglycaemia. 5 Moreover, in addition to CHO content, post-meal glucose concentrations are also influenced by many other factors that are dis- 45 However, late postprandial hypoglycaemia was induced in 50% of the participants. 45 They tested their system in outpatient settings, in which they reduced the median glucose and increased percentage of time spent in target range, but still had a higher percentage of time in hypoglycaemia 44 and no difference for postprandial median glucose as compared with CSII. 47 The latter studies only compared fully automated CLS to CSII, whereas some compared fully automated CLS with hybrid CLS using patient-driven administration of meal boluses. For example, Weinzimer et al. showed
an important reduction in daytime plasma glucose levels and postprandial peak glucose levels with the addition of a partial meal-priming bolus in comparison with their fully automated CLS. 34 This group was also the only one to test a fully automated system combining insulin and pramlintide as discussed below (adjunctive therapy), 39 a combination that needs to be further explored.
Despite promising results for some CLS and for meal detection algorithms 49 there is still a need for robust, outpatient, randomized trials to demonstrate the efficacy of fully automated CLS in controlling postprandial glucose levels. Patients' acceptance of a fully automated CLS needs to be examined. Its potential to improve quality of life is probable but should be obtained while aiming concomitantly for an optimal glucose control.
| CLS with simplified meal bolus
Additional strategies have been tested in combination with CLS in order to reduce or avoid the need for CHO counting (Table 2 ). In a pilot project, a prandial bolus based on body weight (0.047 U of insulin per kg) was compared with a CHO-matched bolus within the context of dual-hormone CLS. 50 This weight-based meal bolus resulted in prolonged glycaemic excursion and it is unlikely to provide an acceptable postprandial glucose control. In a subsequent inpatient trial, the efficacy of dual-hormone CLS combined with a CHO-matched bolus was compared with dual-hormone CLS combined with a meal bolus based on semi-quantitative CHO content assessment: a patient's current insulin-to-CHO ratio and meal category (regular meal or large meal).
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The simplified strategy tested yielded an overall comparable mean blood glucose with, however, higher postprandial glucose excursions compared with CHO-matched bolus after meals with >90 g of CHO.
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In a following outpatient study, additional meal categories were created and the efficacy of the simplified bolus strategy was compared with CHO-matched boluses in the context of single and dual-hormone CLS. 51 No difference was observed for any outcome between the simplified strategy and the CHO-matched boluses using both CLS sys- 
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With this strategy, patients have to select a meal (breakfast, lunch or dinner), and then select a meal size: typical, more than usual, less than typical or a small bite. 16, 48 The meal-priming bolus administered corresponds to 75% of the average prandial insulin provided for previous meals of the same size and at the same time of day. This approach preserves the benefits of meal announcement to improve the overall CLS performance while largely relieving the burden associated with CHO counting. The latest outpatient automated studies using this strategy have demonstrated the merits of this approach in improving glucose control in both adults and children. 16, 48 In the current context, informing the algorithm of a meal is probably a needed compromise. By announcing a meal, the system is bet- 
| CHALLENGES AND TECHNICAL ISSUES
In the following section, challenges and issues pertaining both to CLS components and human factor error or influence will be discussed.
Current main technical issues regarding CLS components include limitations due to current insulin pharmacodynamics (PD) and PK. Other 
| Insulin PK/PD
Plasma glucose concentration typically rises within 10 minutes following food ingestion and it is expected to return to the pre-meal level within 2 to 3 hours, although nutrient absorption can continue for up to 5 to 6 hours post-meal. 54 Indeed, several factors discussed below can affect the rise in BG and nutrient absorption, such as meal composition, meal timing and gastric emptying. In healthy individuals, insulin is secreted in response to meal consumption in a timely and synchronized manner to adequately control rising BG levels. This synchronized insulin response is lost due to the subcutaneous route of insulin replacement in T1D. The major challenge to control post-meal glucose control is thus the delayed PK/PD with subcutaneously administered insulin. 55 Rapid-acting insulin analogs (Lispro, Aspart and Glulisine) are used with CSII and in CLS, and the onset of these insulin preparations is between 10 and 15 minutes, with a peak action between 1 and 2 hours. 2 Even with the current rapid-acting insulin analogs, the post-meal glucose absorption is much faster than insulin absorption through the subcutaneous tissue. This mismatch largely explains the inability of current CLS to control postprandial glucose excursions and the increased risk of late postprandial hypoglycaemia in response to important reactive insulin infusion with fully automated CLS. 34, 36 This time lag between fast acting insulin absorption and meal absorption has motivated research towards faster acting insulins. 
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This new insulin has not yet been tested in CLS, but will likely generate interest. Use of other avenues such as insulin combined with hyaluronidase to hasten insulin absorption could also represent promising alternatives for postprandial glucose improvement.
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The intra-peritoneal insulin infusion route is technically challenging but advantageous in terms of pharmacokinetics for glucose regulation as compared with the subcutaneous route because insulin is delivered mainly in the portal vein rather than systemically, which is far closer to normal physiology, allowing a larger and direct effect on hepatic glucose production regulation. 62 Intra-peritoneal insulin infusion is associated with tight glucose control and a low hypoglycaemia incidence. 63, 64 CLS with intra-peritoneal insulin infusion from an implanted pump has been tested showing improved glucose control as compared with open-loop intra-peritoneal insulin infusion. 65 Comparison of this strategy to subcutaneous CLS and in larger studies is warranted.
| Sensor accuracy and delays
The accuracy and reliability of the CGMS is also of importance in CLS. These devices have considerably evolved over time, are increasingly accepted by patients and healthcare professionals, and shown to improve glycaemic control in adult patients with T1D. 66 CGMS readings are measured in the interstitial fluid, which can differ from plasma BG due to the time delay needed to equilibrate glucose between the blood vessels and interstitial fluid compartments. The time delay can vary from 3 to 12 minutes and is highest when BG levels are rapidly changing, such is the case post meals or during exercise. 67, 68 These sensor delays remain one of the main challenges faced by CLS algorithms and can affect the efficacy of the artificial pancreas in regards to meals. Other than time delays, CGMS performance can be influenced by calibration errors and delays from patients or from capillary glucose meter values. 67 Inaccuracies related to the device itself such as errors in signalling, noise filtering or positional stability are additional variables. 69, 70 The accuracy of the CGMS has considerably improved, 71 however, errors can be challenging in study protocols; for example, sensor failure due to inaccuracy or loss of signal was reported in 28% of the experiments during the hybrid CLS safety trial by Zisser et al. 72 Over time, in a context of proper usage, particularly in relation to proper calibration, 73 such as ideal timing and frequency, the performance of CGMS has improved significantly with the newer generations; the measurement error has been reduced to about 10% with most devices. 74 Nevertheless, CLS algorithms need to adequately account for the limitation of these devices (eg, a sensor underestimation of actual blood glucose will lead to increased postprandial glucose excursions) and patient education about optimal use of CGMS devices is crucial to operate CLS safely and effectively.
| Nutrient absorption and effect of other macronutrients
Several factors can impact glucose absorption such as gastric emptying, physical activity, alcohol consumptions and meal composition. showed that a high-fat meal compared with a low-fat meal with similar protein and CHO content resulted in more insulin requirements and increased BG. 79 Accurate CHO counting is an essential aspect to manage postprandial BG levels in T1D 22 and already constitutes a challenging task for most patients with T1D 5, 6 ; thus, adding protein and lipid aspects to prandial insulin bolus calculations would considerably increase the complexity of post-meal glucose control for patients. In CLS, a meal bolus strategy that does not require proteins and lipids counting without compromising post-meal glucose control would greatly simplify patients' treatment. As the time associated with the effect of lipids and proteins on postprandial BG is relatively long (approximately 5 hours), CLS is expected to have the time to adjust in response to changing BG levels. However, well-designed studies are needed to answer this important question.
| Insulin sensitivity variations
Postprandial glucose control is also challenged by the considerable intra-and inter-individual variability in the metabolic effect of subcutaneous insulin infusion in patients with T1D. 80, 81 For the same body weight and age, insulin sensitivity can vary by up to 6-fold between individuals. Across daytime, a significant range of in-between meals insulin sensitivity also exists, with an increasing sensitivity from breakfast to lunch. 81 In addition, within the same individual but across days, it is estimated that there is 31% variability in insulin sensitivity overnight and 17% variability during the day. 82 Patients'
insulin-to-CHO ratios will thus often vary across the day. 83 Other factors also effect insulin sensitivity, such as physical activity, physical or emotional stress, growth and hormonal fluctuations (puberty, pregnancy, menopause, menstrual cycle). 2 Next generation algorithms with adaptive properties are expected to account to some extent for these variabilities and individualize treatment through enhancement of the day-to-day learning process.
| Behavioral challenges
Safe and adequate use of CLS is necessary to avoid compromising glucose control. Many outpatient studies have now been conducted without serious adverse events reported. The FDA has even approved the first system for commercialization. However, some safety issues will need to be addressed with patients. An entirely automated system has the potential in adults to improve quality of life by releasing patients from daily burdensome tasks. It could be particularly beneficial for patients with poor adherence to meal insulin boluses and children and adolescents. In children, limitations for postprandial glucose control include, for example, unpredictable appetite, difficulty in foreseeing the beginning of food intake, limited communication and collaboration. For overnight glucose control, a CLS approach has been shown to be feasible and effective for hypoglycaemia risk reduction. 12, 84, 85 Yet, daytime CLS studies in young children are scarce. A recent study in a small number of young children showed decreased mean BG without increased hypoglycaemia during a 68-hours period as compared with conventional therapy with a CLS system adapted for young children. 86 Adolescence is also known as a difficult period for glucose control, with important physiological changes impacting insulin sensitivity 87 and a low-adherence to diabetes self-treatment plan, 88 including omission [89] [90] [91] or underestimation 92 of insulin boluses for meals and snacks. Omission of meal boluses appears to be common, with 65% of youths using CSII who would miss at least 1 meal-time bolus per week. 90 In most cases, adolescents would simply be unaware of missed boluses 90 ; yet, it is also possible that insulin boluses were omitted to limit hypoglycaemia risk or to control weight. A tendency in female adolescents to skip or reduce insulin doses for weight control purposes has been observed in several studies. 93, 94 The efficacy and safety of hybrid CLS control could thus be compromised in youths who voluntarily or accidentally omit boluses. One study demonstrated safety of CLS glucose control in the context of reduction or omission of meal bolus. 95 Following the bolus omission of a 55 g of CHO lunch, hyperglycaemia was not prevented despite an increased insulin infusion; yet, hypoglycaemia risk was not increased in the 5.5-hours postprandial period. 95 Following an unannounced snack and a reduced meal bolus, CLS also improved short-term glucose control as compared with usual care without increasing hypoglycaemia risk in adolescents. 96 Thus, the safety of the system (hypoglycaemia) appears to be preserved with bolus omission, yet postprandial glucose control (hyperglycaemia) is impaired.
| Multi-hormone CLS and adjunctive therapies
Multi-hormone systems are identified, alongside insulin-only auto- 39, 106 In combined insulin/pramlintide therapy, the meal is extended, allowing more time for adequate feedback to CLS to adjust insulin, possibly improving glucose control. An ongoing study is investigating the effect of continuous pramlintide infusion using subcutaneous pumps in addition to insulin on overall glucose control (NCT02814123). Future studies will reveal if technical issues would arise with continuous pramlintide infusion through pumps. Potential side effects with pre-meal pramlintide use include nausea and an increased risk of hypoglycaemia, particularly in hypo-unaware patients. 107 These as well as any additional side effects will need to be closely monitored in CLS studies.
The hope is for pramlintide to help fully close the loop around meals or at least allow for some meal-priming without the need for accurate Several technical issues related to multi-hormone systems will, however, need to be addressed before such systems are made available to patients. These issues include the added complexity of such a system, the additional pumps and catheters needed or the need for a dual-chamber pump, the more complex interactions that the algorithm needs to manage, the safety issues in the event of pump or catheter failure (eg, inability to deliver a glucagon bolus) and the necessity to develop stable and safe hormones (eg, glucagon, pramlintide) that can be used in a pump.
| CONCLUSION
The hybrid artificial pancreas is now available to patients. Its efficacy is undisputed and patients have high expectations of this system.
However, to be adopted by patients and clinicians, the device needs to improve glucose control as well as improve quality of life, or at least reduce some burden associated with diabetes management.
Postprandial glucose excursions remain too large with most systems and need to be improved. These systems could lead to alleviation or simplification of CHO counting; however, this benefit should not be detrimental to overall glucose control. The optimal meal strategy for insulin boluses is yet to be determined and several challenges still need to be tackled.
